Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
Specific Aim 1: Characterize the effects of vitamin D treatment on expression of α4β7 on B cells in patients with inflammatory bowel disease (IBD). Specific Aim 2: Determine the effects of vitamin D treatment on fecal immunoglobulins, percentage of Ig-coated gut bacteria, gut microbiome composition (global and bound by immunoglobulins) in patients with IBD and the association of these parameters with change in α4β7+ B cells . Specific Aim 3: Compare BCR repertoire (BCR clonotypes, immunoglobulin heavy chain gene (IGHV), and isotype usage) between α4β7+ and α4β7- B cells in patients with IBD and identify α4β7+ BCR clonotypes associated with Ig-bound gut bacteria .
Official Title
Vitamin D Regulation of α4β7+ B Cell Immunophenotypes and Mucosal Antibody Response to Commensal Gut Bacteria in Patients With Inflammatory Bowel Disease
Eligibility Criteria
- * Adult patients (18 years or older) with inflammatory bowel disease (ulcerative colitis or Crohn's disease)* Low serum vitamin D (25(OH)D ≤ 25 ng/mL* Not currently on high dose vitamin D supplementation* No prior bowel resections* No antibiotic use in past 3 months.
- * Patients less than 18 years old* No diagnosis of IBD* Serum 25(OH)D \> 25 ng/mL* Patients already on vitamin D supplementation* Prior history of bowel surgery (colectomy or small bowel resections)* Recent antibiotic use in past 3 months* Renal Dysfunction* History of Hypercalcemia* History of HIV* History of IgA deficiency* History of Common Variable Immunodeficiency (CVID)* Active C. diff infection
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
John Gubatan, MD
650-725-3362
View on ClinicalTrials.gov
